Form 4: Hims & Hers CLO Sells Shares Under 10b5-1 Plan

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, sold 2,637 shares of Class A Common Stock for $50.1 per share pursuant to a pre-arranged trading plan.

Summary

• Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported a sale of company stock.
• The transaction involved the disposition of 2,637 shares of Class A Common Stock.
• The shares were sold at a price of $50.1 per share.
• The sale occurred on October 27, 2025.
• Following this transaction, Soleil Boughton beneficially owns 158,493 shares of Class A Common Stock directly.
• The sale was executed under a Rule 10b5-1 trading plan, which was adopted on August 28, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan, which typically does not indicate a change in management's outlook or company performance.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to new, non-public information.

Negatives

• An insider sale, even if pre-scheduled, reduces the officer's direct equity stake in the company.

Future Outlook

N/A

Industry Context

This filing is specific to an individual insider transaction at Hims & Hers Health, Inc. and does not provide broader industry context or trends. Insider sales under 10b5-1 plans are common across industries for executives managing personal finances.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the pre-scheduled nature mitigates concerns about management confidence. The volume is too small to significantly impact market liquidity or price.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction.

Key Dates

Keywords

Hims & Hers, HIMS, Form 4, Insider Trading, Stock Sale, Soleil Boughton, Chief Legal Officer, 10b5-1 plan, Equity Disposition